Sharps Technology, Inc. (STSS)
NASDAQ: STSS · Real-Time Price · USD
5.36
0.00 (0.00%)
Aug 14, 2025, 8:53 AM - Market open
Company Description
Sharps Technology, Inc., a medical device and pharmaceutical packaging company, engages in the design, research and development, manufacturing, and commercialization of safety syringe products in the United States.
The company provides safety syringe products comprising Securgard, Sologard, and Sharps Provensa that are ultra-low waste syringes for passive, and safety and reuse prevention features, as well as develops prefillable syringe systems.
The company was incorporated in 2017 and is based in Melville, New York.
Sharps Technology, Inc.
| Country | United States |
| Founded | 2017 |
| IPO Date | Apr 14, 2022 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 55 |
| CEO | Robert Hayes |
Contact Details
Address: 105 Maxess Road, Suite 124 Melville, New York 11747 United States | |
| Phone | 631-574-4436 |
| Website | sharpstechnology.com |
Stock Details
| Ticker Symbol | STSS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.25 |
| CIK Code | 0001737995 |
| CUSIP Number | 82003F309 |
| ISIN Number | US82003F1012 |
| Employer ID | 82-3751728 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Robert M. Hayes | Chief Executive Officer and Director |
| Paul Kruger Danner III | Executive Chairman |
| Andrew R. Crescenzo CPA | Chief Financial Officer |
| Ben Scheu | Vice President of Sales |
| Frank Parrado | Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 13, 2025 | 10-Q | Quarterly Report |
| Aug 5, 2025 | DEFR14A | Filing |
| Aug 5, 2025 | DEFR14A | Filing |
| Jul 28, 2025 | DEF 14A | Other definitive proxy statements |
| Jul 18, 2025 | PRER14A | Filing |
| Jul 18, 2025 | 8-K | Current Report |
| Jul 3, 2025 | 8-K | Current Report |
| Jul 3, 2025 | PRE 14A | Other preliminary proxy statements |
| Jun 6, 2025 | SCHEDULE 13G/A | Filing |
| Jun 4, 2025 | 8-K | Current Report |